Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
Key Highlights
- ➤Sibylla appoints Usman Azam CEO and Gianluca Fuggetta CFO
- ➤Lidia Pieri becomes COO; Elena Ardini promoted to chief scientific officer
- ➤Cyclin D1-targeting degrader advances as Sibylla’s lead clinical program
- ➤Sibylla targets first-in-human studies with folding-interference protein degradation
Expert Statements
Dieter Weinand, Chairman of the Board of Sibylla Biotech
“Sibylla has evolved as an organization, making this the right time to expand the executive team and drive further momentum. Usman brings a powerful combination of company building and oncology research and development experience to lead Sibylla toward first-in-human studies. This progress would not have been possible without the strong foundation Lidia built as founding CEO, and we highly value her continued leadership as we enter this new chapter. The Board and I are convinced that the team is well positioned to accelerate the development of Sibylla’s highly differentiated protein degradation approach and emerging oncology pipeline.”
Usman Azam, CEO of Sibylla Biotech
“By pursuing protein folding interference, Sibylla has the potential to expand the druggable proteome, unlocking therapeutic protein targets that have historically presented significant development challenges. Early intervention and disruption of the protein folding process represents an entirely new mechanism and class of degraders that could change the oncology treatment paradigm”
Usman Azam, CEO of Sibylla Biotech
“Together with our world-class executive team, Sibylla is focused on advancing its lead program targeting Cyclin D1 into the clinic and validating the therapeutic potential of this novel protein degradation approach.”
* Lidia Pieri to serve as Chief Operating Officer and Elena Ardini promoted to Chief Scientific Officer * Cyclin D1-targeting folding-interfering degrader advances as Sibylla’s lead program Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain with the company in the role of Chief Operating Officer. Sibylla also announced the promotion of Elena Ardini, MSc, from Vice President, Research and Development to Chief Scientific Officer. The executive leadership team expansion highlights the company’s progress in validating its differentiated folding interference protein degradation technology and its commitment to bringing its lead program into clinical evaluation.
Get started
Create a free account to read the full story.